Finance

Beta
Lists
RNAC:NASDAQ
Cartesian Therapeutics Inc
$9.64
+2.34%
(+0.22) 1D
$10.20
+5.81% (+0.56)
After hours
Closed: Jun 29, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RNAC...
Open
$9.59
High
$9.65
Low
$9.14
Mkt. cap
283.24M
Avg. vol.
390.93K
Volume
1.00
52-wk high
$15.49
52-wk low
$5.60
EPS
-$5.90
Beta
0.66
Shares outstanding
29.38M
No. of employees
75
Open
$9.59
High
$9.65
Low
$9.14
Mkt. cap
283.24M
Avg. vol.
390.93K
Volume
1.00
52-wk high
$15.49
52-wk low
$5.60
EPS
-$5.90
Beta
0.66
Shares outstanding
29.38M
No. of employees
75
News stories
From sources across the web
About Cartesian Therapeutics Inc
CEO-
Employees75
Founded2007
HeadquartersFrederick, Maryland, United States
SectorBiotechnology
Websitecartesiantherapeutics.com
Analyst ratings
Based on 8 analysts giving stock ratings to RNAC in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for RNAC in the last 3 months.
Highest
Current $9.64
$44.00 (+356.43%)
Average
$33.83 (+250.93%)
Lowest
$16.00 (+65.98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Martin Fan
Wedbush
Buy
Maintained
$38.00
+294.2%
06/10/2026
Unknown Analyst
Wedbush
Buy
Maintained
$38.00
+294.2%
06/10/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$40.00
+314.9%
06/09/2026
Gil Blum
Needham
Buy
Reiterated
$40.00
+314.9%
06/09/2026
Julian Harrison
BTIG
Buy
Reiterated
$44.00
+356.4%
06/09/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
-
-
05/27/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Maintained
$25.00
+159.3%
05/26/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/06/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$16.00
+66%
04/30/2026
Matthew Biegler
Oppenheimer
Hold
Reiterated
-
-
03/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
298.00K
452.00K
947.00K
78.00K
Cost of goods sold
14.87M
13.80M
14.69M
19.46M
Cost of revenue
14.87M
13.80M
14.69M
19.46M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.24M
7.72M
8.20M
7.11M
Operating expense
7.24M
7.72M
8.20M
7.11M
Total operating expenses
22.11M
21.52M
22.89M
26.58M
Operating income
-21.81M
-21.07M
-21.94M
-26.50M
Other non operating income
649.00K
516.00K
702.00K
91.00K
EBT including unusual items
15.89M
-35.90M
-101.77M
-39.18M
EBT excluding unusual items
-19.41M
-19.00M
-19.97M
-25.38M
Income tax expense
-
-
-9.19M
-
Effective tax rate
-
-
9.03%
-
Other operating expenses
-
-
-
-
Net income
15.89M
-35.90M
-92.58M
-39.18M
Net profit margin
5,330.87%
-7,942.92%
-9,775.71%
-50,233.33%
Earnings per share
-0.77
-0.73
-2.71
-0.95
Interest and investment income
1.75M
1.55M
1.27M
1.03M
Interest expense
-
-
-
-
Net interest expenses
1.75M
1.55M
1.27M
1.03M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.22M
-20.46M
-21.33M
-25.88M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer